The U.S. Food and Drug Administration has approved a monthly maintenance dosing regimen for Leqembi, an Alzheimer’s drug developed by Japan’s Eisai and its partner Biogen, the companies announced on Monday. The decision is expected to improve treatment convenience for patients.
The U.S. Food and Drug Administration has approved a monthly maintenance dosing regimen for Leqembi, an Alzheimer’s drug developed by Japan’s Eisai and its partner Biogen, the companies announced on Monday. The decision is expected to improve treatment convenience for patients.
Leave a Comment
Your email address will not be published. Required fields are marked with *